Breaking News
Imiquimod has a favorable clinical profile for treating superficial basal cell carcinoma
Imiquimod has a favorable clinical profile for treating superficial basal cell carcinoma
A prospective, observational, multicenter study gathered information on the effectiveness and safety of imiquimod 5% cream in 370 adults with superficial basal cell carcinoma in daily practice. Patient satisfaction was also assessed. Imiquimod was applied 5 times weekly for 6 weeks; patients recorded treatment events on diary cards and had a final visit within 16 weeks of the end of treatment. In total, 471 tumors were evaluated, most of which were primary. The clearance rate was 83.2% and was independent of tumor size. Most patients (85%) had erythema, which was severe in 24%. Nine patients discontinued because of skin reactions. Overall 82.1% of patients were satisfied or very satisfied with imiquimod ...
Last updated: Thursday, December 29, 2011
AccessDermatology | © Copyright 2011 Prous Science S.A.U. a Thomson Reuters business or its licensors.
All rights reserved. Legal Information. Send your comments to Webmaster
ISSN 2013-8202
This website is optimized for Explorer 7.0 and above, Firefox 3.0, Safari, and Chrome. Content remains viewable in older versions, but loss of formatting and design elements may occur.
This site complies with the HONcode standard for trustworthy health information:
verify here.